Disability morbidity and group life mortality can be significantly influenced by advancements in medical science and technology. Recent examples include gene-based therapies, GLP-1 medications, mRNA vaccine technology, and more. In this session, the panelists will review these recent medical advancements and share their thoughts on the potential impact these changes could have on the disability and group life markets.
- Future Actuaries
-
Education & Exams
Educational Pathways Associate of the Society of Actuaries (ASA) Fellow of the Society of Actuaries (FSA) Chartered Enterprise Risk Analyst (CERA) Micro-Credentials
- Professional Development
-
Research Institute
Aging & Retirement Artificial Intelligence Catastrophe and Climate COVID-19 Disability Diversity Equity & Inclusion Finance & Investment General Insurance Global Health Care Cost Trends Innovation & Technology Life & Annuities Long-Term Care Mortality & Longevity Predictive Analytics & Modeling Risk Management U.S. Population Valuation/IllustrationsSponsorships Proposal Requests Data Requests Calls for Papers Funding & Grants Competitions & Awards Academic & Student Research
- Communities
-
Tools & Resources
- About SOA
- Future Actuaries
-
Education & Exams
- Professional Development
-
Research Institute
-
Aging & Retirement Artificial Intelligence Catastrophe and Climate COVID-19 Disability Diversity Equity & Inclusion Finance & Investment General Insurance Global Health Care Cost Trends Innovation & Technology Life & Annuities Long-Term Care Mortality & Longevity Predictive Analytics & Modeling Risk Management U.S. Population Valuation/Illustrations
-
- Communities
-
Tools & Resources
-
About SOA
-
Topics in the News